170 related articles for article (PubMed ID: 28836710)
1. Airway plaque presenting after alteration of immunosuppression in a pediatric patient remote from heart transplantation.
Ryan TD; Absalon MJ; de Alarcon A; Gupta A; Peters AL; Lorts A; Danziger-Isakov LA; Chin C
Pediatr Transplant; 2017 Nov; 21(7):. PubMed ID: 28836710
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus DNA monitoring in serum and whole blood in pediatric liver transplant recipients who do or do not discontinue immunosuppressive therapy.
Kullberg-Lindh C; Saalman R; Olausson M; Herlenius G; Lindh M
Pediatr Transplant; 2017 Aug; 21(5):. PubMed ID: 28039929
[TBL] [Abstract][Full Text] [Related]
3. Low viral load post-transplant lymphoproliferative disease localized within the tongue.
Henry DD; Hunger SP; Braylan RC; Dharnidharka VR
Transpl Infect Dis; 2008 Dec; 10(6):426-30. PubMed ID: 18657087
[TBL] [Abstract][Full Text] [Related]
4. Rapidly progressive post-transplant lymphoproliferative disease following withdrawal of sirolimus.
Mendelson M; Barday Z; Eastman R; Le Feuvre D; Candy S; Wu HT; Swanepoel C
S Afr Med J; 2012 Aug; 102(12):924-6. PubMed ID: 23498038
[TBL] [Abstract][Full Text] [Related]
5. Imaging findings in children with proliferative disorders following multivisceral transplantation.
Hryhorczuk AL; Kim HB; Harris MH; Vargas SO; Zurakowski D; Lee EY
Pediatr Radiol; 2015 Jul; 45(8):1138-45. PubMed ID: 25796382
[TBL] [Abstract][Full Text] [Related]
6. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
[TBL] [Abstract][Full Text] [Related]
7. Post-transplant lymphoproliferative disorder after kidney transplantation: time to adopt monitoring of Epstein-Barr virus?
Biller P; Michaux L; Pauw LD; Camboni A; Mourad M; Kanaan N
Acta Clin Belg; 2015 Jun; 70(3):218-22. PubMed ID: 25541210
[TBL] [Abstract][Full Text] [Related]
8. Primary central nervous system posttransplantation lymphoproliferative disorder after heart and lung transplantation.
Gifford G; Fay K; Jabbour A; Ma DD
Intern Med J; 2015 May; 45(5):583-6. PubMed ID: 25955465
[TBL] [Abstract][Full Text] [Related]
9. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
[TBL] [Abstract][Full Text] [Related]
10. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
[TBL] [Abstract][Full Text] [Related]
11. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
Merlino C; Giacchino F; Bergallo M; Bonello F; Bollero C; Segoloni GP; Cavallo R
G Ital Nefrol; 2003; 20(2):170-5. PubMed ID: 12746803
[TBL] [Abstract][Full Text] [Related]
12. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.
Hart M; Thakral B; Yohe S; Balfour HH; Singh C; Spears M; McKenna RW
Am J Surg Pathol; 2014 Nov; 38(11):1522-9. PubMed ID: 25007145
[TBL] [Abstract][Full Text] [Related]
13. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
[TBL] [Abstract][Full Text] [Related]
14. Surveillance of Epstein-Barr virus infection as a risk factor for post-transplant lymphoproliferative disorder in pediatric renal transplant recipients.
Köpf S; Tönshoff B
Pediatr Nephrol; 2004 Apr; 19(4):365-8. PubMed ID: 14963763
[TBL] [Abstract][Full Text] [Related]
15. Adenotonsillar hypertrophy and Epstein-Barr virus in pediatric organ transplant recipients.
Shapiro NL; Strocker AM
Laryngoscope; 2001 Jun; 111(6):997-1001. PubMed ID: 11404611
[TBL] [Abstract][Full Text] [Related]
16. Posttransplantation lymphoproliferative disorders.
Andreone P; Gramenzi A; Lorenzini S; Biselli M; Cursaro C; Pileri S; Bernardi M
Arch Intern Med; 2003 Sep; 163(17):1997-2004. PubMed ID: 14504111
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus-associated lymphoproliferative disease in oral cavity in a renal transplant recipient: a case report.
Johnson J; Kerecuk L; Harrison M; Taylor JO; Odell E
Pediatr Transplant; 2007 May; 11(3):340-4. PubMed ID: 17430495
[TBL] [Abstract][Full Text] [Related]
18. Post-transplant lymphoproliferative disorder following pediatric heart transplantation.
Mendoza F; Kunitake H; Laks H; Odim J
Pediatr Transplant; 2006 Feb; 10(1):60-6. PubMed ID: 16499589
[TBL] [Abstract][Full Text] [Related]
19. Is murine gammaherpesvirus-68 (MHV-68) a suitable immunotoxicological model for examining immunomodulatory drug-associated viral recrudescence?
Aligo J; Walker M; Bugelski P; Weinstock D
J Immunotoxicol; 2015; 12(1):1-15. PubMed ID: 24512328
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of mTOR by sirolimus induces remission of post-transplant lymphoproliferative disorders.
Boratyńska M; Smolska D
Transpl Int; 2008 Jun; 21(6):605-8. PubMed ID: 18282244
[No Abstract] [Full Text] [Related]
[Next] [New Search]
